Figure 3

The effectiveness of IHoP in preventing hyperglycemia in pre-onset NOD mice treated with an IHoP-siRNA construct. (a) NOD mice were placed into three groups; (1) pre-onset mice (glucose below 100 mg/dl) receiving scrambled construct, as controls (open red circles; n=4); (2) post-onset mice (glucose above 250 mg/dl) receiving IHoP-siRNA (open green diamonds; n=5), and (3) pre-onset mice receiving IHoP-siRNA (open blue squares; n=5). Arrows indicate siRNA injection and color corresponds to treatment group. (b) Glucose-6-phosphatase expression (dark brown in nuclei) in livers from NOD mice treated with IHoP-siRNA. Pre-onset IHoP-siRNA-treated mice had very few hepatocytes stained positively for glucose-6-phosphatase. Nuclei were counterstained with hematoxylin (blue). Scale bars, 20 μm. (c) Blood glucose levels were measured in glucose-challenged (1 g/kg) control mice (white bars) and challenged mice concurrently given i.v. IHoP protein (1 μg/kg; black bars). Data are represented as mean+s.d. of blood glucose levels (n=5). *P<0.01, **P<0.05.